$847,186 R&D Tax Incentive received
Filed with ASX · · 3 pages · English
Melbourne, Australia – Entropy Neurodynamics Limited (‘Entropy Neurodynamics’, ‘ENP’ or the ‘Company’) (ASX: ENP), a clinical-stage biotechnology company, is pleased to confirm receipt of $847,186 for its Research & Development Tax Incentive for financial year 2024 (FY24). The refund relates to Entropy’s eligible expenditure in relation to the ongoing development of lead-asset, TRP-8803 (IV-infuse
Entropy Neurodynamics Limited on 6ix
Story so far
Earlier from Entropy Neurodynamics
- First BED patient completes second TRP-8803 infusion
- First patient successfully dosed in TRP 8803 BED trial
- BED trial accelerates - enrolment grows, dosing in two weeks
- $6.1m in new funding to accelerate clinical development
- Trading Halt
Later from Entropy Neurodynamics
- TRP-8802 Phase 2a Trial Shows Sustained BED Reduction
- First TRP-8803 BED patient shows broad clinical improvement
- Quarterly Activities Report and Appendix 4C
- Australian Patent Secures TRP 8803 Platform to 2042
- Appendix 4D and Half Year Report for period 31 Dec 2025
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics